Mylan, a pharmaceutical company, has introduced lamivudine film coated tablets, 150mg and 300mg, in the UK and Italy.
The generic version of GlaxoSmithKline's Epivir tablets is indicated as part of antiretroviral (ARV) combination therapy for the treatment of HIV-infected adults and children.
The product is the first generic HIV treatment launched by Mylan in Europe, according to the company.
Mylan CEO Heather Bresch said the company contributes to fighting against HIV/AIDS to the European markets with the launch of Lamivudine.
According to IMS Health, Lamivudine Tablets had sales of approximately €3.4m in the UK and sales of approximately €12.5m in Italy for the 12 months ending 31 March 2012.